<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Antibiotics for treating exacerbations of cystic fibrosis lung disease</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Antibiotics for treating exacerbations of cystic fibrosis lung disease</h1>
<div class="graphic"><div class="figure"><div class="ttl">Antibiotics for treating exacerbations of cystic fibrosis lung disease</div><div class="cntnt"><table cellspacing="0"><colgroup span="4" width="18%"></colgroup><colgroup width="28%"></colgroup> <tbody> <tr class="divider_bottom"> <td class="subtitle1">Bacteria</td> <td class="subtitle1">Antibiotic</td> <td class="subtitle1">Pediatric <span class="nowrap_whitespace">dose<sup>*</sup></span></td> <td class="subtitle1">Adult dose</td> <td class="subtitle1">Comments</td> </tr> <tr> <td class="divider_bottom" rowspan="5"><em>Staphylococcus aureus</em><br/> (methicillin-sensitive)</td> <td>Cefazolin</td> <td>100 mg/kg per day in 3 or 4 divided doses</td> <td>1.5 g every 6 hours or 2 g every 8 hours</td> <td>Maximum 6 g per day.</td> </tr> <tr> <td class="indent1" colspan="4"><strong>or</strong></td> </tr> <tr> <td>Nafcillin</td> <td>100 to 200 mg/kg per day in 4 or 6 divided doses</td> <td>2 g every 4 to 6 hours</td> <td>Maximum 12 g per day.</td> </tr> <tr> <td class="border_bottom_white" colspan="4"><strong><em>Oral regimens (for mild exacerbations)</em></strong><sup>¶</sup></td> </tr> <tr class="divider_bottom"> <td class="indent1" colspan="4">One of the following, guided by susceptibility testing: <ul class="decimal_heading"> <li><span class="nowrap_whitespace">Trimethoprim-sulfamethoxazole<sup>Δ</sup></span></li> <li>Doxycycline</li> <li>Amoxicillin-clavulanate</li> </ul> </td> </tr> <tr> <td class="divider_bottom" rowspan="7"><em>S</em>. <em>aureus</em><br/> <span class="nowrap_whitespace">(methicillin-resistant)<sup>[1]</sup></span></td> <td><span class="nowrap_whitespace">Vancomycin<sup>◊</sup></span></td> <td>60 mg/kg per day in 3 (or 4) divided doses</td> <td>45 to 60 mg/kg per day in 3 divided doses</td> <td> <p>Maximum 3.6 g per day for children and 4.0 g per day for adults.</p> These doses are for patients with normal kidney function. Dose and frequency are adjusted based on serum vancomycin concentrations, using either trough-directed or AUC-guided <span class="nowrap_whitespace">dosing<sup>§</sup></span>. To reduce the risk of kidney toxicity, a beta-lactam other than piperacillin-tazobactam should be selected when being used in combination with vancomycin and <span class="nowrap_whitespace">tobramycin<sup>[2]</sup>.</span></td> </tr> <tr> <td class="indent1" colspan="4"><strong>or</strong></td> </tr> <tr> <td>Linezolid</td> <td> <p><strong><em>Children &lt;12 years:</em></strong><br/> 30 mg/kg per day intravenously or orally in 3 divided doses</p> <strong><em>Children ≥12 years:</em></strong><br/> Use adult dose</td> <td>600 mg intravenously or orally every 12 hours</td> <td>Risk of myelosuppression (most commonly thrombocytopenia) with treatment &gt;14 days or when kidney function impairment is <span class="nowrap_whitespace">present<sup>[3]</sup>.</span></td> </tr> <tr> <td class="indent1" colspan="4"><strong>or</strong></td> </tr> <tr> <td>Ceftaroline</td> <td>45 mg/kg per day intravenously in 3 divided doses</td> <td>600 mg intravenously every 8 hours</td> <td>Maximum 1800 mg per day.</td> </tr> <tr> <td class="border_bottom_white" colspan="4"><strong><em>Oral regimens</em></strong><sup>¶</sup></td> </tr> <tr class="divider_bottom"> <td class="indent1" colspan="4">One of the following, guided by susceptibility testing: <ul class="decimal_heading"> <li><span class="nowrap_whitespace">Trimethoprim-sulfamethoxazole<sup>Δ</sup></span> (for mild exacerbations)</li> <li>Doxycycline (for mild exacerbations)</li> <li>Linezolid (for moderate or severe exacerbations)</li> </ul> </td> </tr> <tr> <td class="divider_bottom" rowspan="17"><em>Pseudomonas aeruginosa</em></td> <td colspan="4"><strong>One of the following:</strong></td> </tr> <tr> <td class="indent1"><span class="nowrap_whitespace">Piperacillin-tazobactam<sup>¥‡</sup></span></td> <td>350 to <span class="nowrap_whitespace">450 mg/kg<sup>†</sup></span> per day in 4 divided doses</td> <td>4.5 g every 6 hours</td> <td>Maximum <span class="nowrap_whitespace">16 g<sup>†</sup></span> per day.</td> </tr> <tr> <td class="indent1"><span class="nowrap_whitespace">Ceftazidime<sup>¥</sup></span></td> <td>150 to 200 mg/kg per day in 3 or 4 divided doses</td> <td>2 g every 6 to 8 hours</td> <td>Maximum 8 g per day.</td> </tr> <tr> <td class="indent1">Cefepime</td> <td>150 mg/kg per day in 3 divided doses</td> <td>2 g every 8 hours</td> <td>Maximum 6 g per day.</td> </tr> <tr> <td class="indent1">Imipenem-cilastatin</td> <td>60 to 100 mg/kg per day in 4 divided doses</td> <td>0.5 to 1 g every 6 hours</td> <td>Maximum 4 g per day.</td> </tr> <tr> <td class="indent1">Meropenem</td> <td>120 mg/kg per day in 3 divided doses</td> <td>2 g every 8 hours</td> <td>Maximum 6 g per day.</td> </tr> <tr> <td class="indent1"><span class="nowrap_whitespace">Ticarcillin-clavulanate<sup>¥‡</sup></span></td> <td>400 mg/kg<sup>**</sup> per day in 4 or 6 divided doses</td> <td>3.1 g every 4 to 6 hours</td> <td>Maximum 18 g<sup>**</sup> per day.</td> </tr> <tr> <td colspan="4"><strong>Plus</strong></td> </tr> <tr> <td class="indent1">Ciprofloxacin</td> <td> <p><strong><em>Oral dose:</em></strong><br/> 40 mg/kg per day in 2 divided doses</p> <strong><em>Intravenous dose:</em></strong><br/> 30 mg/kg per day in 3 divided doses</td> <td> <p><strong><em>Oral dose:</em></strong><br/> 750 mg every 12 hours</p> <strong><em>Intravenous dose:</em></strong><br/> 400 mg every 8 to 12 hours</td> <td><strong><em>Maximum dose:</em></strong> <ul class="decimal_heading"> <li><em>Oral dose:</em> 2 g per day in children; 1.5 g per day in adults</li> <li><em>Intravenous dose:</em> 1.2 g per day</li> </ul> <p class="extra_spacing_top">Can be used in preference to aminoglycoside or colistin due to less toxicity, particularly when <em>Pseudomonas</em> is sensitive.</p> </td> </tr> <tr> <td class="indent2" colspan="4"><strong>or</strong></td> </tr> <tr> <td class="indent1">Levofloxacin</td> <td><strong><em>Oral and intravenous dose:</em></strong> <ul class="decimal_heading"> <li><em>6 months to 4 years old:</em> 16 to 20 mg/kg per day in 2 divided doses</li> <li><em>5 to 16 years old:</em> 8 to 10 mg/kg per day every 24 hours</li> </ul> </td> <td><strong><em>Oral and intravenous dose:</em></strong> <ul class="decimal_heading"> <li>750 mg every 24 hours</li> </ul> </td> <td><strong><em>Maximum dose:</em></strong> <ul class="decimal_heading"> <li><em>Oral and intravenous dose:</em> 750 mg per day</li> </ul> <p class="extra_spacing_top">Can be used in preference to an aminoglycoside or colistin due to less toxicity, particularly when in vitro testing demonstrates that the <em>P. aeruginosa</em> is sensitive to levofloxacin.</p> </td> </tr> <tr> <td class="indent2" colspan="4"><strong>or</strong></td> </tr> <tr> <td class="indent1"><span class="nowrap_whitespace">Tobramycin<sup>¶¶</sup></span></td> <td>10 mg/kg every 24 hours<br/> (adjust dose for overweight <span class="nowrap_whitespace">patients)<sup>ΔΔ</sup></span></td> <td>10 mg/kg every 24 hours<br/> (adjust dose for overweight <span class="nowrap_whitespace">patients)<sup>ΔΔ</sup></span></td> <td rowspan="3">Refer to the UpToDate topic on treatment of acute pulmonary exacerbations for a discussion of serum concentration monitoring for aminoglycosides and for dose and interval adjustment for kidney function impairment. Dose and frequency from a previous course that achieved the therapeutic range may be considered for determining the initial dose.</td> </tr> <tr> <td class="indent2" colspan="3"><strong>or</strong></td> </tr> <tr> <td class="indent1"><span class="nowrap_whitespace">Amikacin<sup>¶¶</sup></span></td> <td>30 to 35 mg/kg every 24 hours<br/> (adjust dose for overweight <span class="nowrap_whitespace">patients)<sup>ΔΔ</sup></span></td> <td>30 to 35 mg/kg every 24 hours<br/> (adjust dose for overweight <span class="nowrap_whitespace">patients)<sup>ΔΔ</sup></span></td> </tr> <tr> <td class="indent2" colspan="4"><strong>or</strong></td> </tr> <tr class="divider_bottom"> <td class="indent1">Colistin (colistimethate sodium)</td> <td>2.5 to <span class="nowrap_whitespace">5 mg/kg<sup>◊◊</sup></span> (colistin base <span class="nowrap_whitespace">activity<sup>§§</sup>)</span> per day in 3 divided doses</td> <td>2.5 to <span class="nowrap_whitespace">5 mg/kg<sup>◊◊</sup></span> (colistin-base <span class="nowrap_whitespace">activity<sup>§§</sup>)</span> per day in 3 divided doses</td> <td> <p>Maximum 300 mg per day (colistin-base <span class="nowrap_whitespace">activity<sup>§§</sup>).</span></p> <p>Colistin is a second-line drug that may be useful when the <em>P. aeruginosa</em> demonstrates in vitro resistance to all aminoglycosides or when the patient fails to improve on an aminoglycoside-containing regimen.</p> <strong>IMPORTANT:</strong> Dose units and recommended dosing regimens vary by product and country. Doses shown here are specific to United States-licensed information for Coly-Mycin M, which labels its product as units of "colistin-base <span class="nowrap_whitespace">activity"<sup>§§</sup>.</span> Consult local official product information for details before using this agent. Adverse effects include kidney and neurotoxicities.</td> </tr> <tr class="divider_bottom"> <td><em>S. aureus</em> (methicillin-sensitive)<br/> <strong>and</strong> <em>P. aeruginosa</em></td> <td colspan="4">Same antibiotics shown above for <em>P. aeruginosa</em> alone <strong>EXCEPT</strong> that ceftazidime should not be used, because of poor activity against <em>S. aureus</em>.</td> </tr> <tr> <td rowspan="5"><em>S. aureus</em> (methicillin-resistant)<br/> <strong>and</strong> <em>P. aeruginosa</em></td> <td colspan="4">Same antibiotics shown above for <em>P. aeruginosa</em> alone.</td> </tr> <tr> <td colspan="4"><strong>Plus</strong> one of the following <strong>(3 antibiotics total)</strong>:</td> </tr> <tr> <td class="indent1"><span class="nowrap_whitespace">Vancomycin<sup>◊</sup></span></td> <td>60 mg/kg per day in 3 (or 4) divided doses</td> <td>45 to 60 mg/kg per day in 3 divided doses</td> <td> <p>Maximum 3.6 g per day for children and 4.0 g per day for adults.</p> These doses are for patients with normal kidney function. Dose and frequency are adjusted based on serum vancomycin concentrations, using either trough-directed or AUC-guided <span class="nowrap_whitespace">dosing<sup>§</sup>.</span> To reduce the risk of kidney toxicity, a beta-lactam other than piperacillin-tazobactam should be selected when being used in combination with vancomycin and <span class="nowrap_whitespace">tobramycin<sup>[2]</sup>.</span></td> </tr> <tr> <td class="indent2" colspan="4"><strong>or</strong></td> </tr> <tr> <td class="indent1">Linezolid</td> <td> <p><strong><em>Children &lt;12 years:</em></strong><br/> 30 mg/kg per day intravenously or orally in 3 divided doses</p> <strong><em>Children ≥12 years:</em></strong><br/> Use adult dose</td> <td>600 mg intravenously or orally every 12 hours</td> <td>Risk of myelosuppression (most commonly thrombocytopenia) with treatment &gt;14 days or when kidney function impairment is <span class="nowrap_whitespace">present<sup>[3]</sup>.</span></td> </tr> </tbody></table></div><div class="graphic_lgnd"><p>The table contains recommended choices of antibiotics based on the type of bacteria isolated. The selection should be modified based on results of sensitivity testing and kidney function. The doses given here are typical for patients with cystic fibrosis. Higher and/or more frequent dosing of some antibiotics is often required for cystic fibrosis patients as compared with patients without cystic fibrosis, and a wider range of dose requirements is to be expected. Note that these dosing recommendations do not apply to cystic fibrosis patients who have undergone lung transplantation.</p>
For most of these antibiotics, dosing reflects recommendations from a comprehensive review of antipseudomonal antibiotics in cystic <span class="nowrap_whitespace">fibrosis<sup>[4]</sup>.</span> For a few of the antibiotics (piperacillin-tazobactam, ticarcillin-clavulanate, and ceftazidime), the review recommends much higher doses for cystic fibrosis patients than are used for patients without cystic fibrosis. These are based primarily on pharmacokinetic and pharmacodynamic considerations, but clinical trial data for these very high doses are lacking. Therefore, we suggest intermediate doses for these drugs, as shown in the table above. Many clinicians are prescribing beta-lactam antibiotics to be administered by prolonged or continuous infusion, based on a strong theoretical basis and pharmacokinetic analysis of drug levels in patients with cystic fibrosis.</div><div class="graphic_footnotes"><p>AUC: area under the time-concentration curve; MIC: minimum inhibitory concentration; MSSA: methicillin-sensitive <em>S. aureus</em>.</p>
<p>* The dose given to children generally should not exceed the dose for adults.</p>
<p>¶ The severity of an exacerbation is typically based on changes in clinical symptoms and pulmonary function tests compared with the patient's own baseline.</p>
<p>Δ For trimethoprim-sulfamethoxazole, dosing for patients with cystic fibrosis may need to be higher than that recommended for non-cystic fibrosis patients (refer to the UpToDate topic on treatment of acute pulmonary exacerbations in cystic fibrosis).</p>
<p>◊ For vancomycin, some clinicians target a lower serum trough level of 10 to 15 mg/mL since this reduces the risk for nephrotoxicity, and pharmacokinetic/pharmacodynamic studies showed that this approach achieves the desired target of AUC/MIC ≥400 in children and <span class="nowrap_whitespace">adolescents<sup>[5]</sup>.</span></p>
<p>§ For therapeutic monitoring of vancomycin, either trough-directed or AUC-guided strategies may be used. AUC-guided dosing requires support from a clinical pharmacist, and was endorsed by a consensus <span class="nowrap_whitespace">guideline.<sup>[5]</sup></span> Refer to UpToDate content on treatment of pulmonary exacerbations in cystic fibrosis.</p>
<p>¥ For piperacillin-tazobactam, ticarcillin-clavulanate, and ceftazidime, higher doses than those shown may be considered on a case-by-case basis to optimize pharmacodynamic targets in patients with multidrug-resistant pathogens and poor clinical response to initial <span class="nowrap_whitespace">treatment<sup>[4]</sup>.</span> Many clinicians are prescribing beta-lactam antibiotics to be administered by prolonged or continuous infusion, based on a strong theoretical basis and pharmacokinetic analysis of drug levels. Ticarcillin-clavulanate is no longer available in North America, Australia, the United Kingdom, and most of Europe.</p>
<p>‡ For treatment of <em>P. aeruginosa</em> without MSSA, piperacillin without tazobactam or ticarcillin without clavulanate can be used where available (in combination with ciprofloxacin, an aminoglycoside, or colistin, depending on reported susceptibilities).</p>
<p>† Of piperacillin component. Doses &gt;600 mg/kg/day may be considered on a case-by-case basis, but increased risk of toxicity is expected, including serum sickness, anemias, and bone marrow suppression.</p>
<p>** Of ticarcillin component.</p>
<p>¶¶ Monitor aminoglycoside blood levels and creatinine to ensure efficacy and avoid toxicity. The dose and frequency from a previous course of treatment may be used initially if serum concentrations were in the target range and if creatinine clearance is not substantially changed, but drug levels should still be monitored.</p>
<p>ΔΔ For patients with total body weight greater than 120% of ideal body weight, initial dose selection should be based on adjusted body weight or dosing weight. A calculator for ideal body weight and dosing weight in adults is available in UpToDate.</p>
<p>◊◊ If the patient is overweight, the initial dose of colistin should be based on ideal body weight. A calculator for ideal body weight in adults is available in UpToDate.</p>
§§ For an explanation of our recommended colistin dosing for people with cystic fibrosis, refer to the UpToDate content on antibiotic therapy in cystic fibrosis. Conversions: 1 mg <strong>colistin-base activity</strong> (CBA; United States product) = 30,000 international units of colistimethate sodium (CMS; European Union product).</div><div class="graphic_reference">References:
<ol>
<li>Epps QJ, Epps KL, Young DC, et al. State of the art in cystic fibrosis pharmacology optimization of antimicrobials in the treatment of cystic fibrosis pulmonary exacerbations: III. Executive summary. Pediatr Pulmonol 2021; 56:1825.</li>
<li>LeCleir LK, Pettit RS. Piperacillin-tazobactam versus cefepime incidence of acute kidney injury in combination with vancomycin and tobramycin in pediatric cystic fibrosis patients. Pediatr Pulmonol 2017; 52:1000.</li>
<li>Hiraki Y, Tsuji Y, Matsumoto K, et al. Influence of linezolid clearance on the induction of thrombocytopenia and reduction of hemoglobin. Am J Med Sci 2011; 342:456.</li>
<li>Zobell JT, Young DC, Waters CD, et al. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: VI. Executive Summary. Pediatr Pulmonol 2013; 48:525.</li>
<li>Rybak MJ, Le J, Lodise TP, et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2020; 77:835.</li>
</ol>
<p class="extra_spacing_top">Many but not all of the dosing recommendations in this table are reflected in the following source: Zobell JT, Young DC, Waters CD, et al. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: VI. Executive Summary. Pediatr Pulmonol 2013; 48:525.</p></div><div id="graphicVersion">Graphic 59661 Version 23.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
